Korro Bio Return on Equity

Korro Bio (KRRO) currently reports a ROE of -103.31%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Korro Bio's ROE history and peer comparisons.

Korro Bio's ROE of -103.31% is lower than the Healthcare sector average of 20.86%. That is roughly 595.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Korro Bio's current -103.31% should be judged against Healthcare norms (sector average: 20.86%) and against KRRO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -103.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Korro Bio, and consider following KRRO for alerts when major investors trade the stock.

Korro Bio is classified in the Healthcare sector. On ROE, it currently shows -103.31% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KRRO with unrelated industries.